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In multicellular organisms both health and disease are defined by patterns of communica-
tion between the constituent cells. In addition to networks of soluble mediators, cells are
also programed to exchange complex messages pre-assembled as multimolecular cargo of
membraneous structures known extracellular vesicles (EV). Several biogenetic pathways
produce EVs with different properties, and known as exosomes, ectosomes, and apop-
totic bodies. In cancer, EVs carry molecular signatures and effectors of the disease, such
as mutant oncoproteins, oncogenic transcripts, microRNA, and DNA sequences. Intercellu-
lar trafficking of such EVs (oncosomes) may contribute to horizontal cellular transformation,
phenotypic reprograming, and functional re-education of recipient cells, both locally and
systemically. The EV-mediated, reciprocal molecular exchange also includes tumor sup-
pressors, phosphoproteins, proteases, growth factors, and bioactive lipids, all of which
participate in the functional integration of multiple cells and their collective involvement in
tumor angiogenesis, inflammation, immunity, coagulopathy, mobilization of bone marrow-
derived effectors, metastasis, drug resistance, or cellular stemness. In cases where the EV
role is rate limiting their production and uptake may represent and unexplored anticancer
therapy target. Moreover, oncosomes circulating in biofluids of cancer patients offer an
unprecedented, remote, and non-invasive access to crucial molecular information about
cancer cells, including their driver mutations, classifiers, molecular subtypes, therapeutic
targets, and biomarkers of drug resistance. New nanotechnologies are being developed to
exploit this unique biomarker platform. Indeed, embracing the notion that human cancers
are defined not only by processes occurring within cancer cells, but also between them,
and amidst the altered tumor and systemic microenvironment may open new diagnostic
and therapeutic opportunities.
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INTRODUCTION
It could be argued that the ultimate test for the correctness and
utility of concepts explaining the nature of human neoplasia is
not just their intellectual sophistication, but rather the robustness
of therapeutic predictions they inspire. In this regard the justified
enthusiasm over the early experiences with targeted anticancer
agents is increasingly mixed with a sense of surprise that biologi-
cal agents designed to strike at, what is often seen as the very heart
of the malignant process (oncogenic pathways and driver muta-
tions), frequently deliver only partial or temporary effects, rather
than being curative (Murdoch and Sager, 2008).
These limitations could in each case be explained by several
detailed biological mechanisms, many of which are intensively
studied (Broxterman et al., 2003; Bergers and Hanahan, 2008).
However, a part of this conundrum could also lie in the possibility
that some major pieces of cancer pathogenesis puzzle are still miss-
ing, or have been overshadowed by technological developments,
often on the expense of concepts. In this regard there seem to be
at least two self-imposed barriers in the current thinking about
the more effective ways to execute anticancer therapy. First, there
is a tendency to grapple with the uncomfortable complexity of
human cancers through attempts to seek simplicity in their com-
mon denominators, such as those exemplified by the “hallmarks
of cancer” (Hanahan and Weinberg, 2011). While such organiz-
ing principles can be invaluable in the conceptual, fundamental
and educational sense, they also downplay profound distinctions
between disease states that have traditionally been classified as
“cancer,” and are effectively vastly different from one another. It is
unlikely that effective treatment of, say glioblastoma (GBM) could
be derived from first principles that operate above this diversity.
Second, the fascination with the technological ability to detect
and catalog tangible changes in the genome and epigenome of
cancer cells, sometimes leads to the notion that these intra-
cellular events play a causative role in the disease, because of
their selective enrichment (dominance) in the cancer cell pop-
ulation (Vogelstein and Kinzler, 2004; Avraham and Yarden,
2011; Flaherty et al., 2012). This approach has led to spec-
tacular developments in the area of targeted anticancer ther-
apeutics. It also brought the sense that cancer can essentially
be explained (in both general terms and in detail) by inherent
nature of various molecular intracellular alterations, by virtue
of their subsequent Darwinian selection through competition
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of affected cancer cells, or stem cells (Nowell, 1976; Greaves
and Maley, 2012). Consequently, the alternative approaches of
peering through the nebulous questions surrounding “cancer
cell societies,” their complexity, heterogeneity, and inner dynam-
ics (Heppner, 1989; Miller and Heppner, 1990) largely fell out
of favor, wherein may lay some of the currently encountered
limitations.
COMPLEXITY OF HUMAN CANCERS
The advent of molecularly based, targeted drugs brought the hard
scientific rationality into the area of oncology practice (Druker,
2004). Perhaps, the most impressive examples of this invaluable
and lasting impact include the introduction of imatinib into ther-
apy of chronic myelogenous leukemia (CML), trastuzumab into
breast cancer (BCa), sunitinib into renal cancer (RCC), avastin
into colorectal tumors (CRC), and vemurafenib into melanoma
(CMM; Druker, 2004; Flaherty et al., 2012), all of which continue
to stimulate hope and well justified excitement.
On the other hand there is a growing realization that even
within the restrictive subgroups of cancers the disease cannot nec-
essarily be reduced to intracellular iterations of mutations and the
related epistatic signaling defects amenable to suppression by the
respective pharmaceuticals. Indeed, the major genomic and gene
expression profiling projects (e.g., TCGA) have documented the
existence of unsuspected multiplicity of molecular disease vari-
ations, defined by mixtures of prevalent and rare mutations, the
genesis, and causative role of which is not always immediately
obvious (Phillips et al., 2006; Wood et al., 2007; Curtis et al., 2012).
Moreover, the recent progress in the next generation sequencing
technologies (NGS) revealed an even more limitless, evolving, and
highly regional genetic heterogeneity, including cellular diversity
between and within individual lesions in the same cancer patient
(Gerlinger et al., 2012). Indeed, at least in certain disease settings,
distinct genetic defects with a putative disease-propagating poten-
tial seem to exist within each tumor cell, or in their subsets, the
myriads of which may populate tumor masses and distant sites
in individual cancer patients (Turner and Reis-Filho, 2012). Such
intricacies have long evaded traditional molecular profiling efforts,
and they clearly make molecular targeting, and individualized can-
cer care more difficult to conceptualize (as each patient may harbor
multiple disease causing mechanisms).
On the other hand, findings revealing the cellular complexity
of various cancers tend to revive an interest in the actual meaning,
causes, and consequences of tumor heterogeneity, and they pave
the way to studies on the evolution of, and phylogenetic linkages
within, the hierarchical cancer cell subpopulations (Dick, 2008;
Greaves and Maley, 2012; Wu et al., 2012). There is an emerging
realization that functional units of various cancer-related processes
(e.g., stemness, metastasis, angiogenesis) could be pre-programed
within multicellular assemblies rather than in phenotypes of indi-
vidual cancer cells (Rak, 2006; Greaves and Maley, 2012). This
alternative optics sees cancer cell populations as complex systems,
and challenges the traditional tenets of cancer genetics, by placing
considerable emphasis on low frequency events, cryptic cellular
subsets, and cooperation rather than domination of specific cel-
lular clones, all of which may contribute to certain aspects of the
disease (Wood et al., 2007; Gerlinger et al., 2012; Wu et al., 2012).
For example, the concept of “driver mutations” is largely based
on statistical frequency of certain genetic events in the cancer cell
population, and their presumed selective (competitive) and cell-
intrinsic advantage. This is often taken as tantamount to playing
a causative and pathogenetic role in a particular cancer. How-
ever, such mutational preponderance may also reflect the history
rather the driving mechanism of the disease. Indeed, the propen-
sity of a particular gene to mutate early on in the disease process
(hence commonality) may not necessarily prove that the mutation
in question is indispensable at the later stages of cancer progres-
sion. At the very least, the roles of mutational events may be more
complex than can be inferred from their statistical frequencies
and may encode not only cell-autonomous traits, but also define
patterns of intercellular interactions.
A case in point could be the frequent oncogenic amplifications
of the epidermal growth factor receptor (EGFR), or the related
oncogenic mutation (EGFRvIII) in GBM (Wen and Kesari, 2008).
It is thought provoking that mutant EGFR is not sufficient to cause
glioma in animal models (Huse and Holland, 2009). Moreover,
pharmacological targeting of EGFR provides a relatively modest
therapeutic benefit, and only to GBM patients with certain con-
figuration of other molecular changes, such as intact expression
of the PTEN tumor suppressor gene (Mellinghoff et al., 2005).
Notably, GBMs often contain stably mosaic cellular compositions,
including the concomitant presence of tumor cell subsets with and
without EGFRvIII mutation, or co-existing tumor micro-regions
harboring cell subpopulations with oncogenic amplifications of
either EGFR or PDGFR genes (Biernat et al., 2004; Ramnarain
et al., 2006; Inda et al., 2010; Snuderl et al., 2011). This sustained
(active) heterogeneity is not readily detectable by profiling studies
and the reasons why it exists are not always immediately obvi-
ous. Nonetheless, the stable co-existence of genetically distinct cell
subsets suggests that their compositions (cooperation) may be a
source of aggressive disease, and confers a collective, rather than
individual, growth advantage.
It is also of note that the seemingly permanent, selective, and
presumably advantageous genetic alterations (e.g., EGFR amplifi-
cations), are often lost from glioma cells as soon as these cells are
separated from each other and placed in cell culture (Bigner et al.,
1990; Schulte et al., 2012). Regardless of the underlying causes and
mechanisms of this intriguing change, the loss of genetic mutation
upon transfer into a different microenvironment (e.g., in vitro)
suggests that it is the communication with pericellular surround-
ings (in vivo) of these malignant cells that may ultimately control
the status and prevalence of their cell-intrinsic “driver mutations.”
INTERCELLULAR COMMUNICATION IN CANCER
PROGRESSION
Revesz (1956) described an experiment involving injection into
syngeneic mice of either small numbers of viable cancer cells (104),
or much larger numbers (108) of the same cells that have been pre-
viously rendered mitotically dead through the exposure to a high
dose of ionizing radiation. While neither of these inoculations
produced tumors for up to 90 days, they did so when combined
into one injection (Revesz, 1956). In today’s terms this experiment
(Revesz effect ) may suggest that even under the best of condi-
tions the viable tumor initiating cells (TICs) require a supportive
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niche, which could consist of the remaining, even mitotically dead,
or otherwise non-tumorigenic cancer cells, as well as other stro-
mal elements. Although the irradiated cells were, by definition,
devoid of TIC properties, they clearly played other biological
roles by interacting with viable TICs in this setting, a process that
could be linked to paracrine interactions, immune-protection, or
angiogenesis (Rak, 2006).
There are numerous examples of the influence cell-cell interac-
tions may exert over the malignant potential of individual cancer
cells, or their subsets. For example, in their now classical exper-
iments, Mintz and Illmensee isolated normal mouse embryonic
stem (ES) cells and demonstrated that they form aggressive ter-
atomas upon ectopic (subcutaneous) inoculation. Remarkably,
these teratoma cells were able to give rise to normal mice upon
their incorporation into blastocysts, even after repeated passage
as tumors in mice, for several years (Mintz and Illmensee, 1975).
Similarly, Bissell and colleagues discovered that Rouse sarcoma
virus (RSV) was unable to transform avian embryos, but could
cause cancer in analogous chick tissues when injected post birth
(Dolberg and Bissell, 1984). More recently, normal neuronal stem
cells were found to come into contact with, and influence, their
malignant GBM counterparts, at least in part through stimulation
of the vanilloid receptor (TRPV1; Stock et al., 2012).
However, there is probably no better example of the role cellu-
lar interactions play in cancer then the process of metastasis. The
“seed and soil” relationship between metastatic cancer cells and
their organ destinations involves multiple and reciprocal signals,
which are of either selective or instructive nature. Different popu-
lations of cancer cells colonize specific organ sites in a process now
known to be influenced not only by the cancer cell genome, but
also by the host genetic background and tissue microenvironment
(Paget, 1889; Fidler, 2003; Hunter, 2006; Chiang and Massague,
2008). In invasive tumors stromal cells may acquire genetic muta-
tions (Hida et al., 2004; Hill et al., 2005). Both the vasculature and
bone marrow-derived cells (BMDCs) that infiltrate distant organ
sites are involved in the execution of the metastatic niche program
(Folkman and Kalluri, 2003; Kaplan et al., 2005; Peinado et al.,
2012). In some instances only a small (normally undetectable)
proportion of cancer cells may contain genetic determinants asso-
ciated with the metastatic process, and these signatures are only
revealed (enriched) upon tumor dissemination to distant sites
(Gerlinger et al., 2012; Wu et al., 2012). It is possible that in
these settings the rare mutant genes confer interactive phenotypes
unique to the sites of metastasis.
The genetic evolution of cancer cell clones during disease pro-
gression and metastasis is often viewed mainly as a result of
competitive interactions, resulting in the selection of specific and
advantageous cellular traits (Nowell, 1976; Vogelstein and Kinzler,
2004). However, as early as in 1980s Heppner, Miller and their col-
leagues begun exploring the possibility that, at least under certain
circumstances, some of the key events in cancer can be defined
by cellular composition and intercellular cooperation, rather than
being solely an outcome of a Darwinian dominance (Heppner,
1989). Using a unique series of sister cancer cell lines derived from a
single murine mammary tumor, these investigators demonstrated
the cooperative (interactive) paradigm applies to such diverse bio-
logical processes as tumor growth, metastasis, and drug resistance
(Miller and Heppner, 1990). Similar findings have been docu-
mented in more recent studies, again emphasizing that molecular
cell-cell interactions may occur over short and long distances, and
may include paracrine and inflammatory components (McAllister
et al., 2008).
A particularly elegant example of cellular interrelationships in
cancer is described in a recent study by Wu and colleagues. These
investigators embarked on the analysis of the role of the oncogenic
Ras mutation (RasV12) and the loss of scribbled tumor suppressor
(scrib-) in the context of ocular tumor development in Drosophila.
Interestingly, each of these genetic defects alone was found to be
insufficient to trigger the overt eye disease, but their co-existence
in the same ocular cell resulted in formation of aggressive tumors,
thereby revealing the expected genetic cooperation. Perhaps less
expected, but fascinating, was the fact that tumors did emerge
even when RasV12 and scrib− mutations occurred in separate
cellular subsets within the same eye. This suggests that genetically
altered cellular subpopulations may cooperate in forming a pro-
tumorigenic microenvironment, a “critical mass” required for the
onset of the overt disease (Wu et al., 2010). These and other exam-
ples raise the possibility that intercellular exchange of information
(influenced by genetic defects) may play a significant, perhaps a
defining, role in the context of at least some cancers. If this is the
case, the content of molecular information required for cellular
cooperation and the nature of processes leading to such intercel-
lular exchanges, integration, and dialog could be of considerable
diagnostic and therapeutic significance.
EXTRACELLULAR VESICLES AS MEDIATORS OF
MULTICELLULAR INTEGRATION
Interactions between cancer cells and their surroundings are mul-
tifaceted. While the related analyses usually concentrate on cellular
secretome, and molecular recognition events involving soluble or
cell-associated ligands and their receptors, there are several other
levels of intercellular communication worthy of consideration.
Thus, adjacent cells may enter into a deeper level of functional
integration through physical contact and/or exchange of cellular
fragments, a process which may lead to “sharing” of more com-
plex integral segments of molecular machinery of a given cell.
Such exchanges have been described upon formation of intercel-
lular junctions, synapses, cytonemes, or by membrane swapping
processes known as trogocytosis, all of which mostly operate over
short distances (Roy et al., 2011).
In this regard, a unique form of molecular exchange that can
operate over both, short or long distances consists of shedding and
uptake of extracellular vesicles (EVs). EVs are plasma membrane
structures that emanate from all cells, especially upon cellular
stress, activation, or transformation (Thery et al., 2009; Record
et al., 2011; Kalra et al., 2012). Such vesicles originate either at
cell surfaces (ectosomes), or within the endosomal pathway (exo-
somes), the elements of which may subsequently relocate to the
inner portion of the plasma membrane and release exosomes into
the extracellular space. Moreover, vesiculation may also accom-
pany apoptotic cell death, in which case it is a terminal, but
biologically important, process that may influence surrounding
viable cells in several ways, including transfer of mutant, oncogenic
DNA, and stimulation (Bergsmedh et al., 2001).
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It should be emphasized that the abundance, heterogeneity, and
molecular characteristics of EVs reflect not only the identity and
state of their parental cells, but also the diversity of the under-
lying biogenetic pathways (Thery et al., 2009). Thus, exosomes
are usually relatively small (30–100 nm) and upon centrifuga-
tion sediment within a defined sucrose gradient density (1.11–
1.20 g/ml). They are rich in tetraspanins (e.g., CD63, CD81, CD9),
and their production is controlled by several emerging regulatory
mechanisms, including elements of the endosomal sorting com-
plex required for transport (ESCRT), Rab proteins (e.g., Rab27a),
p53/TSAP6 pathway, ceramide, and neutral sphingomyelinase, to
mention the most studied effectors (Yu et al., 2006; Lespagnol
et al., 2008; Trajkovic et al., 2008; Ostrowski et al., 2010; Bobrie
et al., 2012; Peinado et al., 2012).
Membrane-derived ectosomes (microparticles) are normally
much larger (100–1000 nm) then exosomes, and they may con-
tain cell lineage markers, cell surface receptors, and often (but
not always) abundance of phosphatidylserine (PS) residues. Their
production is regulated by a distinct set of molecular mechanisms
including AKT activation, acidic sphingomyelinase, intracellu-
lar calcium fluxes, and enzymes involved in the maintenance of
membrane phospholipid asymmetry (Piccin et al., 2007; Bianco
et al., 2009; Di Vizio et al., 2009; Thery et al., 2009). In cancer,
ectosome-like structures may originate from membrane blebs that
are associated with the ameboid motility of certain types of tumor
cells. These abnormal EVs are often referred to as large oncosomes
(Di Vizio et al., 2009).
The emerging evidence points to several additional pathways
involved in cellular vesiculation, the strict assignment of which
to exosome, ectosome, or oncosome production is not always
clear. This includes EGFR, Ras, RhoC/ROCK, DRF3, Arf6, Rap2b,
MEKK2, and other signaling modules (Greco et al., 2006; Di Vizio
et al., 2009; Muralidharan-Chari et al., 2009; Cronan et al., 2012; Li
et al., 2012). Given the link between many of these regulators and
processes that control cellular growth, survival, and motility, it is
not surprising that oncogenic pathways, such as those triggered by
mutant EGFR, MET, K-ras, AKT, and the loss of tumor suppres-
sors, including p53 or PTEN, influence the nature and composition
of tumor-derived EVs. It is possible that the emission of EVs rep-
resents one of several ways in which oncogenic transformation
re-programs the patterns of intercellular interactions, to serve as a
mechanism that conditions tissue microenvironment to promote
(or curtail) neoplastic growth (Rak and Guha, 2012).
Production of EVs is thought to fulfill different basic cellular
functions. In some instances cells simply dispose of the spent or
harmful molecular content in this manner, as is the case for trans-
ferrin receptors during erythrocyte maturation, as well as during
vesicular shedding of complement complexes, or pro-apoptotic
caspase 3 (Johnstone, 2006; Abid Hussein et al., 2007). EVs may
also play a role in modulation of cellular signaling patterns, e.g., by
“deporting” certain activated modules to attenuate their intracel-
lular regulatory influence. This has been postulated to occur in the
case of EGFR, beta-catenin, or viral LMP1 proteins (Chairoung-
dua et al., 2010; Verweij et al., 2011; Garnier et al., 2012). Moreover,
the EV-mediated release of certain membrane-associated ligands,
such as the Notch agonist, delta like 4 (Dll4), may change the
signaling characteristics of the respective pathways (e.g., from
stimulation to inhibition) and in an autocrine, or paracrine man-
ner (Sheldon et al., 2010). Exosomes may also enable formation of
morphogenetic gradients of various mediators required for organ
development, as suggested by the recent studies on Wnt (Gross
et al., 2012). They may also contribute to tumor-stromal interac-
tions (Ghosh et al., 2010; Luga et al., 2012). In a broader sense,
circulating EV may act as important systemic carriers of molecu-
lar information and be involved in modulation of the immune,
inflammatory, hemopoietic, and hemostatic functions. Conse-
quently, null mutations within the exosomal pathway often lead to
anemia, bleeding, and immunological complications (Piccin et al.,
2007; Tolmachova et al., 2007; Lespagnol et al., 2008; Thery et al.,
2009).
The ability of EVs to selectively assemble multiple bioac-
tive molecules, such as signaling and regulatory proteins, lipids,
mRNA, microRNA, and DNA sequences, carries an intrinsic
potential to transfer of this material to various recipient cells capa-
ble of the efficient EV uptake (Ratajczak et al., 2006; Valadi et al.,
2007; Thery et al., 2009). For these reasons EVs are sometimes
referred to as intercellular “signalosomes” (Record et al., 2011).
This property is often seen as a unique pathway of molecular and
functional integration and modulation of multicellular processes.
EVs act across cellular boundaries and make the respective mol-
ecular regulators available to cells that normally do not express
them endogenously, or do so at low levels. We propose that this
circumstance may assume a particular significance in the context
of cancers.
THE EMERGING ROLE OF EXTRACELLULAR VESICLES IN
CANCER
Cancer cells exhibit an altered, and usually pronounced, tendency
to produce EVs (vesiculate). This may be reflected by numbers of
emitted EVs, their sizes, structures, overall protein content, and
the composition of their molecular cargo (Al-Nedawi et al., 2008;
Di Vizio et al., 2009; Palma et al., 2012; Peinado et al., 2012). Both
tumor cells and their activated host counterparts (macrophages,
fibroblasts, platelets) may release EVs into the tumor microenvi-
ronment and circulating biofluids (e.g., blood, lymph, or ascites;
Figure 1). This creates a hitherto unappreciated potential for the
intercellular exchange of bioactive cancer-related macromolecules
(both soluble and cell-associated), between ostensibly distinct cell
types. This process that has recently emerged as an important
modulator of the antitumor immunity, inflammation, angiogen-
esis, thrombosis, invasion, metastasis, resistance to therapy, and
other key biological events (Andre et al., 2004; Dolo et al., 2005;
Taylor and Gercel-Taylor, 2005; Gesierich et al., 2006; Ratajczak
et al., 2006; Bebawy et al., 2009; Camussi et al., 2010; Hendrix
et al., 2010; Hood et al., 2011; Zwicker et al., 2011; Peinado et al.,
2012).
A unique aspect of the EV production by cancer cells is related
to the extracellular emission and intercellular trafficking of mol-
ecules containing oncogenic mutations (Al-Nedawi et al., 2008;
Rak and Guha, 2012). This includes activated oncoproteins, their
transcripts, oncogenic DNA sequences, and oncogenic, as well as
regulatory micro RNA (oncomiRs; Al-Nedawi et al., 2008; Skog
et al., 2008; Holmgren, 2010; Pegtel et al., 2010; Balaj et al.,
2011; Demory et al., 2012; Garnier et al., 2012). Indeed, studies
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FIGURE 1 | Implications of the vesiculation process in cancer.
Heterogeneous populations of cancer and host cells remain functionally
interconnected. This process is, at least in part, mediated by extracellular
vesicles (EVs) that shuttle molecules between different populations of cancer
cells and between them and the non-transformed host stromal and blood
cells. Cancer cells may include stem cell-like compartment (e.g., cells
expressing CD133), or cells that express other surface molecules (MET,
EGFR, EPCAM – see text) with important functions. Some of the more
notable EV-mediated molecular exchanges described recently in the literature
include: (i) transfer of oncogenes (ONC) from cancer cells to normal cells, a
possible horizontal transformation of these cells resulting in changes in
phenotype, as well as (in some cases) acquisition of tumorigenic properties;
(ii) transfer of tumor suppressors (TSG), such as PTEN between cells, with a
possible impact on negative control of cellular transformation; (iii) transfer of
MET receptors from metastatic cancer cells to myeloid cells (CD11b+) to
modulate metastatic niche effects; (iv) contribution of platelet-derived EVs
(CD41+) to the metastatic phenotype of cancer cells, and several other
effects; (v) shedding of EVs by activated endothelium (CD31+). While
tumor-derived EVs constitute a minority within the pool of particles circulating
in plasma, they can be detected for diagnostic purposes. The diagnostic and
therapeutic opportunities, and challenges associated with studies on cellular
vesiculation are described in the text in detail.
performed in a number of experimental systems suggest that
oncogene-containing EVs (oncosomes) can mediate intercellu-
lar trafficking of mutant molecules, once thought to be strictly
intracellular. The uptake of this transforming cargo by indolent
or normal recipient cells was found to cause changes in their
phenotype and biological behavior. For example, the uptake of
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oncogenic EGFR (or EGFRvIII) mediated by this mechanism
causes an apparent phenotypic transformation of indolent glioma
cells, and leads to reprograming of growth factor pathways in nor-
mal endothelial cells (Al-Nedawi et al., 2008, 2009; Skog et al.,
2008).
Other oncogenes, such as Ras, Myc, SV40 LT, LMP1 were also
reported to traffic between cells as cargo of various types of
EVs, whereupon they induce signaling and gene expression effects
across cellular boundaries and often at a distance from their cel-
lular sources (Bergsmedh et al., 2001; Balaj et al., 2011; Demory
et al., 2012; Verweij et al., 2012; Meckes et al., 2010). Conversely,
the discovery of EV-mediated transfer of tumor suppressors, such
as PTEN, has led to a suggestion that such mechanism may cur-
tail the aggressiveness of cancer cells, which may be able to take
up this material from their indolent, or non-transformed and
PTEN-proficient counterparts (Lee et al., 2011; Putz et al., 2012).
It should be mentioned that the effects caused by the uptake
of oncogenic proteins (or nucleic acids) may vary considerably
in different cellular contexts. In some instances the recipient
cells undergo a relatively transient phenotypic transformation, or
exhibit accelerated growth rate, clonogenicity, and proangiogenic
activity (Al-Nedawi et al., 2008). However, the uptake of apoptotic
bodies containing mutant genomic sequences encoding H-ras,
Myc, or SV40 LT (DNA) have been reported to cause an overt
tumorigenic conversion of immortalized fibroblasts (Bergsmedh
et al., 2001). Similarly, permanent changes sufficient to drive
tumor growth in vivo were also described in fibroblasts sub-
jected to the EV-mediated transfer of tumor cell-derived tissue
transglutaminase and fibronectin (Antonyak et al., 2011).
Moreover, the intercellular vesicular trafficking of various
bioactive molecules has long been implicated in metastasis (Poste
and Nicolson, 1980; Janowska-Wieczorek et al., 2005; Hao et al.,
2006; Jung et al., 2009; Hood et al., 2011; Peinado et al., 2012).
A particularly striking recent example in this regard entails the
ability of metastatic melanoma cells to emit exosomes containing
high levels of the MET proto-oncogene. The uptake of this recep-
tor by host BMDCs leads to their stable “re-education,” whereby
they become conditioned to support formation of pre-metastatic
niches in target organs to which melanoma cells can subsequently
lodge (Peinado et al., 2012). Interestingly, an avid uptake of MET
by myeloid cells is not only observed in experimental settings, but
also occurred in stage IV melanoma, as indicated by the high levels
of MET staining on the surface of the circulating BMDCs in these
patients (Peinado et al., 2012).
Tumor-derived EVs may also be enriched in clusters of non-
mutated, but otherwise biologically active regulatory proteins.
Their composition may be reflective of the identity and state
of their parental cells, and could possess diagnostic, as well as
functional significance, for various aspects of disease progression.
This includes wild type growth factor receptors (EGFR, HER-2,
or MET), procoagulant receptors (tissue factor), heat shock pro-
teins (HSP70), angiogenic molecules (IL-8), proteolytic enzymes
(MMPs), and other bioactive cargo (Rak and Guha, 2012).
While the role of vesicles in the intercellular trafficking of onco-
genic and tumor promoting molecules is highly intriguing, the
indispensability of this process during progression of human can-
cers remains unclear, and is likely context-specific. For example,
in the model of A431 carcinoma a PS-blocking agent, Diannexin,
inhibits the uptake of tumor cell-derived EVs by endothelium.
While this leads to antitumor and antiangiogenic effects in vivo,
this impact is only partial, and tumors continue to grow in spite of
daily treatment (Al-Nedawi et al., 2009). It is also noteworthy that
the loss-of-function mutations affecting pathways known to con-
tribute to cellular vesiculation, such as TSAP6 (Yu et al., 2006;
Lespagnol et al., 2008) and acidic sphingomyelinase (Asmase;
Garcia-Barros et al., 2003; Bianco et al., 2009), do not prevent
formation of spontaneous brain tumors in mice injected with
oncogenic vectors (Meehan and Rak, unpublished observation).
Furthermore, the loss of p53 suppressor, which regulates exosome
formation through the TSAP6 activity at least in some settings
(Yu et al., 2006; Lespagnol et al., 2008), in other models promotes
tumorigenesis and EV-mediated shedding of tissue factor by can-
cer cells (Yu et al., 2005). Similarly, silencing of small GTPases
involved in exosome biogenesis (e.g., Rab27a; Ostrowski et al.,
2010), markedly affects melanoma metastasis in mouse models,
but only modestly influences primary tumor growth (Peinado
et al., 2012). In a recent study the antimetastatic effects of Rab27a
manipulations varied considerably between different breast cancer
cell lines revealing a rather“idiosyncratic”effect of this vesiculation
pathway (Bobrie et al., 2012). Thus, specific cancers and the var-
ious processes involved in their distinct pathogenetic trajectories
may differ with respect of the involvement of EVs.
It is possible that the contribution of EVs to cancer progres-
sion, or to the surrounding morbidity and mortality, could also
be affected by other factors, such as host cell properties, host
genetic background, cancer co-morbidities, medication, hormonal
influences, inflammation, and other modifiers, which are presently
poorly defined.
DIAGNOSTIC OPPORTUNITIES ASSOCIATED WITH CANCER
CELL VESICULATION
Accessibility of cancer-related EVs in biofluids, such as plasma,
lymph, cerebrospinal fluid, urine, or malignant ascites or secre-
tions brings to the fore some truly unprecedented diagnostic
opportunities. For example, the analysis of the molecular cargo
associated with circulating oncosomes may provide a unique,
remote, non-invasive, and virtually continuous access to the
changing molecular make up of cancer cells (virtually a “liquid
biopsy”), with significant practical implications. This is a cap-
tivating prospect, as cancer cells themselves are often physically
inaccessible, or cannot be frequently sampled and molecularly
analyzed for obvious technical or ethical reasons.
In this context, the information encapsulated in the EV cargo
(or present on the EV surface) may be especially relevant for
molecular diagnosis of specific cancer subtypes, including mol-
ecular profiling and detection of driver mutations and putative
drug targets. This could be achieved at the protein (Al-Nedawi
et al., 2008; Graner et al., 2009; Shao et al., 2012), mRNA (Skog
et al., 2008), or DNA levels (Balaj et al., 2011). Moreover, EVs rep-
resent a natural mechanism of molecular multiplexing, whereby
they are potentially useful to extract information related to co-
expression of various molecules in parental cancer cells. This
could be useful to extract complex multimolecular classifiers of
specific disease states, therapeutic responses, and clinical features,
including proteomic, transcriptomic, and miR-based signatures
(Skog et al., 2008; Taylor and Gercel-Taylor, 2008; Table 1).
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Table 1 | Possible applications of extracellular vesicles in cancer diagnosis and therapy*.
Potential application Rationale and Hypothetical Effects Relevant literature*
EXTRACELLULARVESICLESASA PUTATIVE DIAGNOSTIC PLATFORM IN CANCER – EXAMPLES
EVs as diagnostic biomarker Molecular diagnosis of cancer subtypes (e.g., marker or multiplex analysis
of EV cargo, derivation of molecular signatures, involving proteins, mRNA,
microRNA, and DNA)
Al-Nedawi et al. (2008), Graner et al.
(2009), Shao et al. (2012)
Correlative diagnostic classifiers (e.g., through developing inventories of
diagnostic proteins, nucleic acids, lipids associated with the EV fraction)
Taylor and Gercel-Taylor (2008)
Detection of circulating EVs containing epithelial markers (e.g., EpCAM and
other molecules normally not found in plasma are often associated with
tumor-derived EVs and can serve as a biomarker of cancer)
Taylor et al. (2011)
EVs as prognostic biomarker Detection of cell-associated molecular markers related to disease
aggressiveness (e.g., expression of oncogenic BRAF, MET, K-ras)
Al-Nedawi et al. (2010),
Ramachandran et al. (2011), Peinado
et al. (2012)
Prognostic signatures (e.g., detection of protein and nucleic acid profiles
associated with specific disease outcomes)
Poste and Nicolson (1980), Taylor
and Gercel-Taylor (2008), Taylor
et al. (2011)
EVs as predictive biomarker Detection of actionable drug targets (e.g., EGFRvIII for the related vaccine;
HER-2 for trastuzumab; BRAF for vemurafenib)
Koga et al. (2005), Al-Nedawi et al.
(2008), Flaherty et al. (2012)
Changes in the levels, nature, state, and composition of drug targets, or
their modifiers (e.g., P-EGFR and PTEN in glioma)
Al-Nedawi et al. (2008), Putz et al.
(2012)
Signatures of cancer cell and cancer stem cell states relevant to therapy
(e.g., indicators of signaling events, stemness, EMT, hypoxia, metabolic
alterations)
Marzesco et al. (2005), Garnier et al.
(2012), Muller (2012)
EVs as drug activity biomarker
platform
Detection of drug target responses to therapeutics (e.g., activated/mutant
states of oncoproteins, changes in levels of related phosphoproteins, gene
expression signatures related to target inactivation or escape)
Al-Nedawi et al. (2008, 2010),
Gonzales et al. (2009)
Detection of correlative markers associated with cellular responses to drug
exposure (e.g., protein levels, markers of stress response, activation of
apoptotic pathways)
Muller (2012)
EVs as a pharmacodynamic
and pharmacokinetic
biomarkers
Markers of drug-target interactions (e.g., drug-target complexes, the
presence of the drug in the EV cargo, as a reflection of drug-cell interaction;
changes down-stream of the expected drug activity, Drug half-life in EVs
versus plasma)
Zhuang et al. (2011), El-Andaloussi
et al. (2012)
EVs as indicators of
resistance to specific
anticancer agents
High levels of circulating EVs containing drug targets and their modifiers
(HER-2-EVs may act as both antagonist and indicators of reduced efficacy
of trastuzumab; the content of HER-3 in breast cancer EVs may suggest
resistance to HER-2 inhibitors)
Ciravolo et al. (2012)
Mutant forms of drug targets (e.g., mutations of EGFR, such as L858R or
T790M in circulating EVs may suggest either sensitivity or resistance to
EGFR inhibitors, respectively; EV-associated mutant K-ras in colon cancer
could be linked to resistance to cetuximab)
Linardou et al. (2009), Siena et al.
(2009)
Target multimerization (e.g., expression patterns of EGFR/HER related
receptors in EVs may be suggestive of changing responses to EGFR or
HER-2 antagonists)
Ritter et al. (2007)
Detection of multidrug resistance markers and mediators (e.g., EVs may
contain ABC transporters and other mediators of resistance to conventional
chemotherapy)
Jaiswal et al. (2011)
(Continued)
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Table 1 | Continued
Potential application Rationale and Hypothetical Effects Relevant literature*
Host-derived EVs as indicators of
changes in the tumor
microenvironment, immunity,
and metabolism
Changes in levels of immune cell-derived EVs (e.g., exosomes may inform
as to the emerging immunosuppression)
Andre et al. (2004)
Presence of tumor antigens on host EVs and evidence of their presentation
(e.g., exosomes emanating from dendritic cells could be informative as to
the state of antitumor immunity; cancer-related exosomes may also have
immune-suppressive activity)
Taylor and Gercel-Taylor (2005), Yang
and Robbins (2011)
Possible evidence of macrophage polarization and bone marrow cell
recruitment (e.g., macrophage-related EVs may carry information as to the
prevalence of M1 or M2 macrophages)
Qian and Pollard (2010)
Possible detection of endothelial cell activation, damage, or death (e.g., in
the context of antiangiogenic therapy endothelial EVs may alter their
numbers, properties, and molecular composition; changes in VEGFR
phosphorylation, IL-6 or IL-8 content, and other features in endothelial EVs
may serve as biomarker of resistance to antiangiogenesis)
Diamant et al. (2004)
EV-associated stromal determinants of cancer progression (e.g.,
stromal-derived exosomes may reflect composition of the cellular
microenvironment in cancer subtypes, and be suggestive of disease
aggressiveness; they may also reflect changes in the physical
microenvironment (hypoxia), and be informative as to therapeutic
responses, angiogenic activity, and other characteristics)
Finak et al. (2008)
EVs as indicators of cancer
associated syndromes
EV-associated prothrombotic activities (e.g., circulating tissue factor
containing EVs may be predictive of cancer coagulopathy or disease
aggressiveness)
Sartori et al. (2011), Zwicker et al.
(2011), van Doormaal et al. (2012)
EV-associated mediators of normal tissue toxicity (e.g., EVs could carry
markers of cardiomyocyte damage, and reflect other toxic side effects that
may occur during anticancer therapy; EV-associated miRs and other
molecules may correlate with the state of affected tissues)
Fichtlscherer et al. (2011)
EXTRACELLULARVESICLESASA PUTATIVETHERAPEUTICTARGETANDTOOL IN CANCER – EXAMPLES
Therapeutic blockade of EV
production by cancer cells
Interference with molecular pathways of exosome biogenesis (e.g.,
silencing of Rab27a/b, neutral sphingomyelinase, and other pathways)
Trajkovic et al. (2008), Ostrowski
et al. (2010), Peinado et al. (2012)
Pharmacological blockade of ectosomal pathways (e.g., targeting
floppases, sphingomyelinases, Rho, Arf6, AKT)
Bianco et al. (2009), Verderio et al.
(2012)
Therapeutic blockade of EV
production by host cells
Inhibition of myeloid cell vesiculation (e.g., FTY720 and other similar acting
agents may influence the EV-mediated components of neuroinflammation,
which may be relevant to the progression of brain tumors; similar effects
could be applicable to other cancers)
Verderio et al. (2012)
Inhibition of vesicular interactions within the angiogenic cell compartment
(e.g., targeting endothelial exosomes may prevent angiogenic interactions
between progenitor cells and mature endothelial cells)
Deregibus et al. (2007)
Therapeutic blockade of EV
uptake
Blockade of surface PS residues with Annexin V analogs and other agents
(e.g., Diannexin and similarly acting agents may prevent EVs from
interacting with surfaces of target cells)
Al-Nedawi et al. (2009)
Blockade of PS receptors on recipient cells (e.g., similar approaches as
above could conceivably also change the surface properties of recipient
cells preventing them from interacting with EVs)
Zhou (2007)
(Continued)
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Table 1 | Continued
Potential application Rationale and Hypothetical Effects Relevant literature*
Blockade of other receptors involved in EV-cell interactions (e.g., PSGL1 is
responsible for interactions between EVs (particles) and cellular P-selectin.
These processes can be antagonized pharmacologically with antibodies and
other agents)
Furie and Furie (2004)
Targeting elements of the EV cargo Antimirs directed at microRNA involved in intercellular communication
(e.g., antagonizing cellular miRs would be expected to deplete them from
the EV fraction)
Zhang et al. (2012)
Kinase inhibitors (e.g., inhibitors of EGFR can impede the consequences of
EV-mediated EGFR transfer between cells)
Al-Nedawi et al. (2008)
Elimination of tumor-related EVs
from the circulation
Medical devices can be used to eliminate cancer derived exosomes from
the circulating blood
Marleau et al. (2012)
Generation of EVs with pathway
antagonistic activity
Interference with signaling pathways by presenting ligands or receptors on
the surface of EVs (e.g., exosomes harboring Dll4 alter Notch signaling in
recipient cells and could modulate tumor angiogenesis)
Sheldon et al. (2010)
EVs as drug delivery systems Exosomes can be engineered to carry therapeutic molecules across tissue
barriers (e.g., EVs can introduce siRNA into brain cells leading to gene
downregulation)
Alvarez-Erviti et al. (2011), Zhuang
et al. (2011), El-Andaloussi et al.
(2012)
EVs may potentially serve as vehicles to deliver tumor suppressors to
cancer cells (e.g., suppressor microRNA, mRNA, and proteins may be
delivered to target cells as cargo of exosomes; horizontal transfer of PTEN
may serve to oppose cellular transformation)
Putz et al. (2012)
EVs as a cancer vaccine platform Dendritic cell-derived exosomes may be used as cell-free cancer vaccine
(e.g., dendritic cells may produce exosomes with the ability to present
cancer antigens while being devoid of the risks and problems associated
with manipulating viable or attenuated cancer cells)
Andre et al. (2004)
*These are presently largely theoretical possibilities, as no approved cancer therapy currently uses EVs as a tool, target, or companion diagnostic. The references do
not provide evidence for these hypothetical scenarios, but merely point to the literature that may be relevant, or suggestive of a potential mechanism that may lead
to EV use, development or feasibility of the respective approaches, as listed in the table.
In some instances the co-expression of molecules within the
same cells may have significant therapeutic consequences and her-
ald sensitivity or resistance to given treatments, e.g., co-expression
of EGFRvIII and PTEN in glioma (Mellinghoff et al., 2005). EVs
may be especially attractive in this context as they could preserve
these combinatorial links. This could be particularly meaningful
if EV samples could be used to detect the changing expression
of putative drug targets, effectors of drug resistance, mediators
of cancer-related co-morbidities, and paraneoplastic syndromes.
These features may have both prognostic and therapeutic signif-
icance (Table 1). For example, there is an emerging interest in
the role of EVs in assessing the risk of cancer patients to develop
thrombotic disorders (coagulopathy). In some (but not all) cases
this condition has been linked to the increase in plasma levels
of tissue factor-bearing EVs and studies are underway to ver-
ify the applicability of this approach (Sartori et al., 2011; Thaler
et al., 2012). Similar opportunities could also exist with regards to
monitoring cancer cachexia, toxic organ damage, or inflammation
(interleukins).
Amongst the most intriguing features of oncosomes is that, at
least to some extent, they preserve the integrity, post-translational
state and activation of oncogenic and regulatory proteins. This
may facilitate detection of the effects exerted by biological agents
directed against specific oncogenic targets, or as mentioned earlier,
signal the emerging resistance to targeted therapy. For exam-
ple, in animal models the phosphorylation status of the EV-
associated and tumor cell-derived EGFR (P-EGFR) can be detected
in plasma using a simple ELISA assay. Interestingly, P-EGFR levels
change in response to EGFR inhibitors, and in concert to anti-
cancer responses observed in these animals (Al-Nedawi et al.,
2010).
At least in theory, EVs may also provide valuable informa-
tion as to other post-translational modifications of key cel-
lular proteins, as well as valuable sequence data indicative of
either pre-existing, or new mutations within those molecules
that may serve as therapeutic targets. Such mutations may be
informative as to sensitivity or therapeutic resistance to certain
drugs (e.g., EGFR inhibitors), molecular progression of the dis-
ease on, or off therapy, or could be related to the onset of
an invasive phenotype. Interestingly, molecular EV cargo shifts
markedly during epithelial to mesenchymal transition (EMT),
or changes as a function of cellular stemness, and these changes
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may have biomarker utility (Marzesco et al., 2005; Garnier et al.,
2012).
Tumor-related EVs circulating in blood are relatively numerous
(even if diluted by EVs emanating from host cells), and represent
either the whole cancer cell population, or its segments that have
a sustained access to blood supply. As mentioned earlier, the EV
content is protected from degradation and external influences,
and remains relatively stable even upon storage. In principle, these
features would separate EV based biomarkers from those associ-
ated with circulating tumor cells (CTCs), as these cells are rare
and derived mainly from cancer cell subsets with a frank ability to
intravasate. Thus, considerable advantages may exist in exploring
the potential of EVs as a cancer biomarker platform.
While diagnostic exploration of EVs has attracted significant
attention, the related technical challenges are also formidable
(Figure 1). Tumor-derived EV often constitute a small minority
amongst the circulating host EVs (<1%), and their contribution
may vary depending on tumor type, size, and barriers of entry
into different fluid spaces, as well as their unique and variable
half lives in the circulation (Wang et al., 2012). In this regard
new technologies of EV isolation, purification, and cargo analysis
are being rapidly developed, including high sensitivity PCR tech-
niques, such as BEAMing (Noerholm et al., 2012), new molecular
profiling platforms (Kosaka et al., 2010), and multiplex microflu-
idics approaches with ultrasensitive detector systems based on
nuclear magnetic resonance (NMR; Shao et al., 2012; van Door-
maal et al., 2012). Indeed, several theoretical possibilities of using
EVs as reservoirs of cancer biomarkers are under consideration
(Table 1). While promising and attractive, these approaches are
also complex and still poorly supported by mechanistic knowledge
of the vesiculation processes in various cancer settings. Conse-
quently, the impact of this field on clinical practice may still be
years away.
THERAPEUTIC POTENTIAL OF EXTRACELLULAR VESICLES IN
CANCER
There are several, still largely theoretical, possibilities of exploiting
the vesiculation process for the purpose of anticancer therapy. For
example, in contexts where EV trafficking has a documented role
in tumor formation, angiogenesis or metastasis, targeting path-
ways of EV production may hold promise. This notion has been
explored through targeting Rab27a and sphingomyelinases in var-
ious settings, with encouraging but also often variable, results
(Bobrie et al., 2012; Peinado et al., 2012; Verderio et al., 2012).
Likewise, blocking the EV uptake pathways may be worthy of
more thorough consideration. Such an effect could be achieved by
obliterating the relevant receptors on the surface of either tumor-
derived EVs (e.g.,PS),or the recipient cells to prevent the respective
contact and merger. Alternatively, the interference with processes
of EV pinocytosis could be considered as a way to achieve simi-
lar effects. Some of these possibilities have already been explored
in aforementioned experiments with Annexin V analogs. Even
though these agents are able to efficiently cloak PS residues in vitro,
and are well tolerated in vivo, their antitumor effect is limited (Al-
Nedawi et al., 2009). Perhaps the most impressive in this regard are
the previously described studies on metastatic melanoma, where
targeting Rab27a led to a significant suppression of metastatic
niche effects, albeit with only a modest impact on the growth of
primary tumors (Peinado et al., 2012). Once again, this example
may suggests that the rate limiting role of EVs may be more pro-
nounced against the metastatic disease then in the context of bulky
tumors. Therefore it is conceivable that adjuvant use of EV antago-
nists may prevent the dissemination of cancer cells and expansion
of dormant tumor foci.
It should be mentioned that cellular vesiculation could be
therapeutically attractive for several additional reasons (Figure 1;
Table 1). For example, exosomes are being explored as cancer
vaccines (Andre et al., 2004), or as possible carriers of biological
therapeutics. The latter avenue created understandable excitement
because of the ability of engineered exosomes to pass through the
blood brain barrier (BBB). To achieve this objective Alvarez-Evriti
and colleagues devised a clever and effective method involving
mast cell-derived exosomes manipulated to express brain pene-
trating 29-mer peptide (RVG) fused to Lampb2 vesicular mem-
brane protein. Such exosomes equipped with a molecular key to
unlock the BBB were used as vehicles to deliver anti-BACE1 siRNA
to either cultured cells or brains of mice, in both cases resulting in
a significant and specific target gene knockdown (Alvarez-Erviti
et al., 2011; Ohno et al., 2012).
In another study the clinically approved sphingosine analog
(FTY720) was recently shown to attenuate EV-mediated neuroin-
flammation (Verderio et al., 2012). These and other emerging
examples illustrate how the biology of vesiculation may be eventu-
ally translated to the realm of anticancer therapy (Table 1). Indeed,
targeting the cancer ‘ecosystem’ may require measures beyond
targeting individual ‘species’ of cancer cells.
SUMMARY
It could be argued that the next major leap in our understanding
of human cancer(s), and in gaining a better therapeutic control
over these diseases (in their spectacular diversity), could come
from studies on what occurs between cancer cells and not only
within them. Oncogenic pathways not only alter the intracellular
microenvironment, but also play a role in formation of aberrant
intercellular communication milieu. This involves the impact of
mutant genes on cancer cell secretome, but also on their vesic-
ulation patterns and the ability to communicate by molecular
exchange with their wider surroundings (cancer cell interactome).
It is striking that some of the cancer-driving mutations persist only
under certain external conditions and disappear from cultured
cells.
Extracellular vesicles are a fascinating and unique part of this
multicellular dynamics. They play still poorly defined pathogenetic
roles but their targeting in cancer is of considerable interest. How-
ever, the ability of cancer (and stromal) cells to vesiculate is already
being explored as a unique and natural mechanism to remotely
reveal the complexity of molecular anomalies associated with
human cancers. In this regard, EVs are the likely carriers of what
is often described as circulating “cell-free” nucleic acids in plasma
(cfNAs; microRNA and DNA), something that has long attracted
diagnostic interests (Schwarzenbach et al., 2011). It is of interest
to explore whether this could be extended to methylation pro-
files and studies on events affecting chromatin architecture. Using
the EV fraction rather than total plasma in these studies could
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offer a significant enrichment opportunity, and enable detection
of rare mutant sequences, other alterations, and their cell-specific
combinations.
Cargo of circulating EVs may also provide clues, as to the repre-
sentation of specific cell types (e.g., stem cells), and other aspects of
tumor cell heterogeneity. The emerging approaches of quantitative
proteomics (e.g., MRM analysis) may extend these opportuni-
ties even further and provide insights into the post-translational
events involved in disease progression (e.g., molecular signaling
states).
It should be noted, however, that major challenges do exist in
all these areas, and the efficient extraction of molecular informa-
tion from highly diluted and heterogeneous EV isolates presents
a formidable technological barrier. Still, the recent developments
are a source of considerable excitement and promise both in terms
of new technologies and new concepts. Indeed, EVs epitomize the
role of intercellular “computing” in complex diseases, such as can-
cer, and they inspire the interest in myriads of other processes that
may underlie the interactomes of individual human tumors.
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